Market Access News | pharmaphorum

News

NICE says no to Lynparza in prostate cancer, creates UK acce...

NICE has said it is unable to recommend NHS use of AstraZeneca's Lynparza for some patients with prostate cancer, after failing to reach an agreement on price with the drugmaker.

News

Life science leaders sign new ‘Biotech Social Pact’ for Europe

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

The EMA's human medicines committee (CHMP) has recommended authorisation of two COVID-19 vaccines from Moderna and Pfizer/BioNTech that include sequences coding for Omicron spike protein as

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer bags first approval for rare skin disease drug

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)

News

Hungary will deploy Brainomix AI stroke software nationwide

UK medtech company Brainomix has claimed its first national contract – from Hungary – for its artificial intelligence-based platform used to improve diagnosis and treatment of people with s

News

Xenpozyme is first FDA-approved drug for rare disease ASMD

Sanofi now has approval on both sides of the Atlantic for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after getting a green light f

News

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Futura Medical's development of a topical treatment for erectile dysfunction (ED) is approaching the finish line in the US, as the UK biotech reports confirmatory phase 3 data ahead of an F

NICE says no to Lynparza in prostate cancer, creates UK acce...

EMA panel backs COVID-19 vaccines targeting Omicron BA.1

Boehringer bags first approval for rare skin disease drug

Hungary will deploy Brainomix AI stroke software nationwide

Xenpozyme is first FDA-approved drug for rare disease ASMD

Futura eyes FDA filing as topical ED drug passes phase 3 tes...

Sanofi drops two more programmes in R&D clear-out

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks